VentureBeat

Circle Pharma Announces Preclinical Data Poster Presentation of CID-078, a First-and-Only-in-Class Cyclin A/B RxL Inhibitor at the 2024 World Conference on Lung Cancer

Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycle therapies, today announced that it presented a digital poster at the 2024 ...
BioWorld

CID-078 has activity in small, non-small-cell lung cancer models

Researchers from Circle Pharma Inc. have presented preclinical data for CID-078, a novel orally bioavailable cyclin A/B Rxl macrocycle being developed for the treatment of patients with lung cancer.
Business Wire

Circle Pharma’s First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor, CID-078, Preclinical Data Highlighted at the 36th EORTC-NCI-AACR Symposium

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, today ...
Morningstar

Circle Pharma Announces Publication in Nature Demonstrating Robust Pre-clinical Anti-tumor Activity of Cyclin A/B RxL Inhibition

Research uncovers how inhibiting interactions between cyclin A and cyclin B and their key binding partners, E2F and MYT1, selectively kills E2F-high tumor cells Circle Pharma’s oral first-in-class ...
VentureBeat

Circle Pharma files first Investigational New Drug application for first-in-class oral cyclin A/B RxL inhibitor for treatment of advanced solid tumors

Circle Pharma, a leader in macrocycle drug discovery and development, announced the submission of its first Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) ...
BioWorld

Cyclin A/B RxL inhibitors for SCLC

Small-cell lung cancer (SCLC) and some other cancers involve dysregulation of the transcription factor E2F, and apoptosis can be induced in those cells by blocking the interaction of the RxL sequence ...
Morningstar

Circle Pharma to Present Trials in Progress Poster on CID-078, a First-in-Class Cyclin A/B Inhibitor, at the ASCO 2025 Annual Meeting

Circle Pharma to Present Trials in Progress Poster on CID-078, a First-in-Class Cyclin A/B Inhibitor, at the ASCO 2025 Annual Meeting Circle Pharma, a clinical-stage biopharmaceutical company ...
Business Wire

Compelling Data in Breast Cancer Treatment with First-In-Class Cyclin A/B Inhibitor Presented at 2023 AACR-NCI-EORTC International Conference

SAN FRANCISCO--(BUSINESS WIRE)--Circle Pharma, in collaboration with the laboratory of Violeta Serra, Ph.D., at Vall d’Hebron Institute of Oncology (VHIO) in Barcelona, Spain, recently unveiled ...